Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve Men

Schoots, 2015, Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review, Eur Urol, 67, 627, 10.1016/j.eururo.2014.10.050 Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 389, 815, 10.1016/S0140-6736(16)32401-1 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Thompson, 2016, The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer, J Urol, 195, 1428, 10.1016/j.juro.2015.10.140 Moldovan, 2017, What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel, Eur Urol, 72, 250, 10.1016/j.eururo.2017.02.026 Fütterer, 2015, Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature, Eur Urol, 68, 1045, 10.1016/j.eururo.2015.01.013 Borofsky, 2018, What are we missing? False-negative cancers at multiparametric MR imaging of the prostate, Radiology, 286, 186, 10.1148/radiol.2017152877 Le, 2015, Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology, Eur Urol, 67, 569, 10.1016/j.eururo.2014.08.079 Nordström, 2018, Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer, Prostate Cancer Prostatic Dis, 21, 57, 10.1038/s41391-017-0024-7 Magheli, 2010, Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience, J Urol, 183, 126, 10.1016/j.juro.2009.08.139 Jue, 2017, Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy, Urology, 105, 123, 10.1016/j.urology.2017.04.015 Distler, 2017, The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction, J Urol, 198, 575, 10.1016/j.juro.2017.03.130 Hansen, 2017, The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7–10 prostate cancer in a repeat biopsy setting, BJU Int, 119, 724, 10.1111/bju.13619 Washino, 2017, Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients, BJU Int, 119, 225, 10.1111/bju.13465 Mehralivand, 2018, A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification, JAMA Oncol, 4, 678, 10.1001/jamaoncol.2017.5667 Rais-Bahrami, 2015, Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies, BJU Int, 115, 381, 10.1111/bju.12639 Kuhl, 2017, Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen, Radiology, 285, 493, 10.1148/radiol.2017170129 Jambor, 2017, Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial), J Magn Reson Imaging, 46, 1089, 10.1002/jmri.25641 De Visschere, 2016, What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?, Eur Radiol, 26, 1098, 10.1007/s00330-015-3894-x Filson, 2016, Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies, Cancer, 122, 884, 10.1002/cncr.29874 Boesen, 2018, Assessment of the diagnostic accuracy of biparametric magnetic resonance imaging for prostate cancer in biopsy-naive men, JAMA Netw Open, 1, e180219, 10.1001/jamanetworkopen.2018.0219 Moore, 2013, Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group, Eur Urol, 64, 544, 10.1016/j.eururo.2013.03.030 Weinreb, 2016, PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2, Eur Urol, 69, 16, 10.1016/j.eururo.2015.08.052 Mottet, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003 Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Epstein, 2016, The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system, Am J Surg Pathol, 40, 244 Zlotta, 2013, Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men, J Natl Cancer Inst, 105, 1050, 10.1093/jnci/djt151 Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0ng per milliliter, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Fascelli, 2016, Combined biparametric prostate magnetic resonance imaging and prostate-specific antigen in the detection of prostate cancer: a validation study in a biopsy-naive patient population, Urology, 88, 125, 10.1016/j.urology.2015.09.035 Van Der Kwast, 2013, Defining the threshold for significant versus insignificant prostate cancer, Nat Rev Urol, 10, 473, 10.1038/nrurol.2013.112